Product profile
LIBERTY Endovascular Robotic System
LIBERTY is Microbot Medical’s FDA-cleared, single-use robotic system for remote guidewire, catheter and guide-catheter navigation during peripheral endovas...
Facts
- Company
- Microbot Medical
- Product type
- surgical_robot
- Status
- fda_cleared
- Primary capability
- peripheral endovascular robotic navigation
- Website
- https://www.microbotmedical.com/liberty/
About LIBERTY Endovascular Robotic System
LIBERTY is a compact, single-use robotic system that lets a physician remotely manipulate guidewires, catheters and guide catheters during peripheral endovascular procedures. AccuGrip controls provide fine advancement and rotation from a position away from the radiation source while preserving use of conventional compatible interventional devices.
The disposable architecture avoids permanent capital equipment and extensive room installation, with setup designed to take less than five minutes. Microbot Medical supplies a starter configuration, training and procedure support around the cleared system. Its current FDA indication covers peripheral endovascular navigation and should not be extended to coronary or neurovascular procedures without separate authorisation.
Market context
https://www.globenewswire.com/news-release/2026/06/30/3319669/0/en/Microbot-Medical-Increases-Manufacturing-Capacity-as-Demand-for-the-LIBERTY-System-Rises-Enters-into-Strategic-Agreement-with-Sanmina-a-Global-Manufacturing-Leader.html, medical_robot, single-use robotic system, d6dd318ac88adc997488267789b31512a0ddfff163e2059e54e802aff1dd4591, Endovascular Surgical Robot, https://www.microbotmedical.com/wp-content/uploads/2026/03/Device.png, https://www.microbotmedical.com/liberty/, FDA 510(k) cleared, products/notion-missing-media/2026-07-30/batch4/liberty-studio-16x9.png, reference_preserving_studio_background_edit, surgical_robot, Endovascular Surgical Robot, Peripheral endovascular procedures; not intended for coronary or neurointerventional procedures, surgical_robot, endovascular_surgical_robot, surgical_robot
Summary
Type: Endovascular surgical robot
Core: LIBERTY
Function: Remote vascular procedure
Audience: Hospitals
Specifications
- intended_use
- Remote delivery and manipulation of guidewires and catheters, and remote manipulation of guide catheters, in the peripheral vasculature
- regulatory_status
- FDA 510(k) cleared on 8 September 2025
- scope_limit
- Not intended for coronary or neurointerventional procedures
- setup_time_min
- Company states setup in under five minutes min
- use_model
- Single-use remotely operated endovascular robotic system
Operations
- Environment
- hospital, interventional_suite
- Primary user
- interventional_physicians, hospital_teams
- Role
- peripheral_endovascular_navigation
- Interaction model
- remote_operator_control
- Mobility class
- compact_tabletop_system
- Product detail
- https://www.globenewswire.com/news-release/2026/06/30/3319669/0/en/Microbot-Medical-Increases-Manufacturing-Capacity-as-Demand-for-the-LIBERTY-System-Rises-Enters-into-Strategic-Agreement-with-Sanmina-a-Global-Manufacturing-Leader.html, medical_robot, single-use robotic system, d6dd318ac88adc997488267789b31512a0ddfff163e2059e54e802aff1dd4591, Endovascular Surgical Robot, https://www.microbotmedical.com/wp-content/uploads/2026/03/Device.png, https://www.microbotmedical.com/liberty/, FDA 510(k)...
Research, Articles and recent verified events
- Microbot Medical adds Sanmina manufacturing capacity for LIBERTY — 2026-06-30
- Microbot Medical expands LIBERTY commercial footprint to seven Eastern U.S. states — 2026-06-23
- Microbot Medical adds first Michigan LIBERTY healthcare-system customer — 2026-06-09
- Microbot Medical secures first North Carolina LIBERTY customer — 2026-06-02
- Microbot Medical receives first international LIBERTY marketing approval — 2026-05-26
- Microbot Medical reports multiple LIBERTY account wins after full release — 2026-05-05
- Microbot Medical starts U.S. limited market release for LIBERTY — 2025-11-05
- Microbot Medical closes $25.2 million preferred-option exercise tranche — 2025-09-16